Compare Amphastar Pharmaceuticals Inc (AMPH) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Under Armour Inc Class A — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Under Armour Inc Class A trades at $5.24 (market cap $2.48B). The key difference: Under Armour Inc Class A is far larger — about 2.9× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | UA | |
|---|---|---|
Market Cap | $863.95M | $2.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $7.88 |
52-Week Low | $16.87 | $3.96 |
Enterprise Value | $1.26B | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Under Armour (UA) trades at $5.925, down 5.2% with bearish technical signals. The company reported mixed Q2 2026 results with an earnings beat but faces revenue declines and negative profitability metrics. Recent news highlights lowered fiscal 2027 revenue outlook due to softer consumer demand in key markets. Cash flow remains negative with significant operational challenges.
The outlook remains challenging with declining revenue trends and negative margins. While analyst consensus shows mixed sentiment, the stock faces headwinds from competitive pressures and execution risks. Investment opportunity exists only for those betting on a successful turnaround despite current fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
